KIR2DS1–HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials
Titel:
KIR2DS1–HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials
Auteur:
Kaddu-Mulindwa, Dominic Altmann, Bettina Robrecht, Sandra Ziepert, Marita Regitz, Evi Tausch, Eugen Held, Gerhard Poeschel, Viola Lesan, Vadim Bittenbring, Joerg Thomas Thurner, Lorenz Pfreundschuh, Michael Christofyllakis, Konstantinos Truemper, Lorenz Loeffler, Markus Schmitz, Norbert Hoth, Markus Hallek, Michael Fischer, Kirsten Stilgenbauer, Stephan Bewarder, Moritz Rixecker, Torben Millard